| Literature DB >> 17576450 |
O Ballivy1, W Parker, T Vuong, G Shenouda, H Patrocinio.
Abstract
We assessed the effect of geometric uncertainties on target coverage and on dose to the organs at risk (OARS) during intensity-modulated radiotherapy (IMRT) for head-and-neck cancer, and we estimated the required margins for the planning target volume (PTV) and the planning organ-at-risk volume (PRV). For eight head-and-neck cancer patients, we generated IMRT plans with localization uncertainty margins of 0 mm, 2.5 mm, and 5.0 mm. The beam intensities were then applied on repeat computed tomography (CT) scans obtained weekly during treatment, and dose distributions were recalculated.The dose-volume histogram analysis for the repeat ct scans showed that target coverage was adequate (V(100) >/= 95%) for only 12.5% of the gross tumour volumes, 54.3% of the upper-neck clinical target volumes (CTVS), and 27.4% of the lower-neck CTVS when no margins were added for PTV. The use of 2.5-mm and 5.0-mm margins significantly improved target coverage, but the mean dose to the contralateral parotid increased from 25.9 Gy to 29.2 Gy. Maximum dose to the spinal cord was above limit in 57.7%, 34.6%, and 15.4% of cases when 0-mm, 2.5-mm, and 5.0-mm margins (respectively) were used for prv.Significant deviations from the prescribed dose can occur during IMRT treatment delivery for head-and-neck cancer. The use of 2.5-mm to 5.0-mm margins for PTV and PRV greatly reduces the risk of underdosing targets and of overdosing the spinal cord.Entities:
Year: 2006 PMID: 17576450 PMCID: PMC1891177
Source DB: PubMed Journal: Curr Oncol ISSN: 1198-0052 Impact factor: 3.677
Target coverage for the initial intensity modulated radiotherapy (imrt) plans and repeat computed tomography (ct) scans when 0-mm, 2.5-mm, and 5.0-mm localization uncertainty margins were used a
| V100 | 95.7±0.7 | 85.9±9.8 | 95.6±0.7 | 96.9±4.1 | 95.8±1.4 | 99.1±1.1 |
| V95 | 99.9±0.2 | 97.4±3.9 | 99.8±0.2 | 99.6±1.0 | 99.7±0.4 | 99.9±0.1 |
| D99 | 98.4±0.4 | 94.0±3.2 | 97.9±1.1 | 98.5±2.3 | 97.8±2.0 | 99.9±1.3 |
| V100 | 97.6±0.4 | 94.7±2.9 | 97.5±1.0 | 98.4±1.3 | 95.4±1.4 | 98.7±1.2 |
| V95 | 99.5±0.3 | 97.9±1.6 | 99.3±0.5 | 99.5±0.5 | 98.1±0.5 | 99.7±0.3 |
| D99 | 97.3±1.2 | 91.0±5.6 | 96.0±3.1 | 98.9±2.8 | 91.4±3.2 | 99.7±2.2 |
| V100 | 96.9±1.2 | 88.3±8.3 | 97.9±1.0 | 94.8±5.6 | 96.1±0.4 | 96.8±4.4 |
| V95 | 99.4±0.3 | 95.1±4.5 | 99.3±0.3 | 98.5±2.2 | 98.5±0.4 | 99.4±0.9 |
| D99 | 97.0±1.6 | 85.1±10.5 | 98.0±1.6 | 95.3±5.4 | 90.0±7.1 | 98.9±3.0 |
For the initial imrt plans, values are for the planning target volume obtained by expanding the gross tumour volume (gtv) and clinical target volume (ctv) with 0 mm, 2.5 mm, and 5.0 mm localization uncertainty margins. For the repeat ct scans (recalculated dose distributions), the values are for the gtvs and ctv, given that the localization uncertainty margins were added for planning only.
Reported as a percentage (%) of the absolute volume.
Reported as a percentage (%) of the prescribed dose to the gtvs and ctvs.
V100 = 100% of the prescribed dose; V95 = 95% of the prescribed dose; D99 = the dose delivered to at least 99% of the volume.
Figure 1For this patient, elevation of the shoulder during the repeat computed tomography (ct) scan (right) as compared with the planning ct scan (left) resulted in reduced coverage of the lower neck region because of greater attenuation of the oblique beams. The effect on the prescription isodose (orange) is significant, but influence on the coverage by the 90% isodose (green) is minimal.
Dose to organs at risk (oars) for the initial intensity modulated radiotherapy (imrt) plans and repeat computed tomography (ct) scans when 0-mm, 2.5-mm, and 5.0-mm localization uncertainty margins were used
| Spinal cord | ||||||
| Dmax | 43.1±1.4 | 45.9±3.1 | 45.8±0.8 | 44.9±2.6 | 46.9±0.9 | 43.0±3.3 |
| D1cm3 | 37.9±1.0 | 38.5±2.1 | 41.1±0.6 | 38.8±1.7 | 42.6±1.0 | 38.1±2.1 |
| Brain stem | ||||||
| Dmax | 40.8±8.1 | 42.1±7.4 | 49.5±3.9 | 45.6±5.9 | 55.6±2.6 | 48.4±4.0 |
| D1cm3 | 33.9±8.4 | 34.5±8.2 | 41.8±5.4 | 35.9±6.8 | 49.4±3.3 | 41.2±4.8 |
| Parotid contralateral | ||||||
| Dmean | 24.4±0.6 | 25.9±4.0 | 25.6±0.5 | 26.7±4.4 | 27.7±1.5 | 29.2±5.4 |
| Parotid ipsilateral | ||||||
| Dmean | 25.8±1.6 | 28.1±3.3 | 28.6±3.8 | 31.4±4.3 | 31.2±4.5 | 34.0±5.4 |
| Larynx | ||||||
| Dmean | 30.6±1.5 | 33.4±2.7 | 32.4±32.4 | 35.3±3.8 | 36.9±2.5 | 39.3±3.6 |
| Mandible | ||||||
| D1cm3 | 60.5±3.4 | 61.5±3.9 | 63.3±3.6 | 64.1±4.0 | 66.0±2.8 | 66.9±3.6 |
Values are for the planning organ-at-risk volume (prv) obtained by expanding the spinal cord and brain stem volume with 0 mm, 2.5 mm, and 5.0 mm localization uncertainty margins. No prvs were generated for the parotids, larynx, and mandible.
Values are for the spinal cord and brain-stem volume; the localization uncertainty margins were added for planning only.
Dmax = maximum dose; D1cm3 = the highest dose to a volume of 1 cm3; Dmean = mean dose.
Difference a in the gross tumour volume (gtv) and clinical target volume (ctv) between the repeat computed tomography (ct) scans and the planning ct scans
| Mean difference (%) | +1.6±3.4 | −6.0±10.0 | −1.3±2.6 | +1.7±4.0 |
Percentage of the absolute volume, obtained by comparing the gtv and ctv volumes from the repeat ct scans with the corresponding planning ct scan.